BRIEF-Advaxis announces that phase 2 head and neck cancer study with AXAL advances to second stage
August 11, 2016 at 08:30 AM EDT
* Phase 2 clinical study of axalimogene filolisbac met its stage 1 primary objective
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.